Development of MicroRNAs as Potential Therapeutics against Cancer

Table 3

Clinical trials using miRNA therapy in human cancers.

Drug (company)	Therapeutic agent	Cancer type	Delivery system	Trial status	Clinical trials gov. Identifier
MRX34 (Mirna Therapeutics)	miR-34 mimic	NSCLC, RCC, primary liver cancer lymphoma, melanoma, multiple myeloma, and renal cell carcinoma	LNPs (Smarticles)	Phase I terminated due to immune-related toxicities and deaths	NCT01829971
MesomiR-1 (TargomiRs) (EnGeneIC)	miR-16 mimic	Malignant pleural mesothelioma and NSCLC	EnGeneIC delivered in an EDV nanocell with EGFR antibody surface conjugation	Phase I completed; Expected to enter phase II	NCT02369198
MRG-106 (miRagen Therapeutics)	Anti-miR-155	Cutaneous T cell lymphoma, mycosis fungoides, chronic lymphocytic leukemia, and adult T-cell leukemia	LNA-modified antisense inhibitor	Phase I (active, not recruiting); Phase II (active, not recruiting)	NCT02580552; NCT03713320

Adapted from Balacescu et al. [122] and Rupaimoole and Slack [123]. Abbreviation: LNPs, lipid nanoparticles; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; EDV, EnGeneIC delivery vehicle; EGFR, epidermal growth factor receptor; and LNA, locked nucleic acid.